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Abstract
AIM
To investigate the hypothesis that treatment with 
dimethyl fumarate (DMF) may ameliorate liver 
ischemia/reperfusion injury (I/RI).
METHODS
Rats were divided into 3 groups: sham, control 
(CTL), and DMF. DMF (25 mg/kg, twice/d) was 
orally administered for 2 d before the procedure. 
The CTL and DMF rats were subjected to ischemia 
for 1 h and reperfusion for 2 h. The serum alanine 
aminotransferase (ALT) and malondialdehyde 
(MDA) levels, adenosine triphosphate (ATP), NO × 
metabolites, anti-oxidant enzyme expression level, anti-
inflammatory effect, and anti-apoptotic effect were 
determined.
RESULTS
Histological tissue damage was significantly reduced in 
the DMF group (Suzuki scores: sham: 0 ± 0; CTL: 9.3 
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± 0.5; DMF: 2.5 ± 1.2; sham vs  CTL, P  < 0.0001; CTL 
vs  DMF, P  < 0.0001). This effect was associated with 
significantly lower serum ALT (DMF 5026 ± 2305 U/L vs  
CTL 10592 ± 1152 U/L, P  = 0.04) and MDA (DMF 18.2 
± 1.4 µmol/L vs  CTL 26.0 ± 1.0 µmol/L, P  = 0.0009). 
DMF effectively improved the ATP content (DMF 20.3 
± 0.4 nmol/mg vs  CTL 18.3 ± 0.6 nmol/mg, P  = 0.02), 
myeloperoxidase activity (DMF 7.8 ± 0.4 mU/mL vs  CTL 
6.0 ± 0.5 mU/mL, P  = 0.01) and level of endothelial 
nitric oxide synthase expression (DMF 0.38 ± 0.05-fold 
vs  0.17 ± 0.06-fold, P  = 0.02). The higher expression 
levels of anti-oxidant enzymes (catalase and glutamate-
cysteine ligase modifier subunit and lower levels of key 
inflammatory mediators (nuclear factor-kappa B and 
cyclooxygenase-2 were confirmed in the DMF group.
CONCLUSION
DMF improved the liver function and the anti-oxidant 
and inflammation status following I/RI. Treatment with 
DMF could be a promising strategy in patients with liver 
I/RI.
Key words: Inflammation; Reactive oxidative stress; 
Nrf2; Ischemia; Dimethyl fumarate; Liver
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In this study, we reveal that (1) administration 
of dimethyl fumarate (DMF) significantly reduced 
tissue damage, improved liver function; and (2) DMF 
attenuated oxidative stress and inflammation, and 
raised anti-oxidant status in rats with hepatic ischemia/
reperfusion injury (I/RI). These findings suggest 
that DMF treatment could be a promising strategy to 
improve clinical outcome in patients with liver I/RI.
Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, 
Farzaneh SH, Shimada M, Stamos MJ, Ichii H. Treatment with 
dimethyl fumarate ameliorates liver ischemia/reperfusion injury. 




Liver ischemia/reperfusion injury (I/RI) is a common 
pathologic process caused by many clinical settings, 
such as liver resection, liver transplantation, hypo­
volemic shock, and trauma[1]. Temporary clamping of 
the portal triad, which is a common strategy during 
liver surgery, produces liver I/RI[2] that may result in 
postoperative liver dysfunction[3]. I/R generates reactive 
oxygen species (ROS), which can damage lipids, 
proteins and tissues and lead to local inflammatory 
responses, endothelial and Kupffer cell activation, 
cytokine/chemokine release, and cell apoptosis[4]. The 
I/R­induced oxidative stress and tissue damage involve 
multiple cell signaling pathways that result in liver 
failure[5]. 
BG­12 has been approved by the Food and Drug 
Administration for the treatment of patients with 
multiple sclerosis, in whom it reduces disease activity 
and the progression of relapsing­remitting multiple 
sclerosis[6]. Dimethyl fumarate (DMF), which has a mild 
side effect profile, has been available for medical use 
for over twenty years, despite an unclear mechanism 
of action. Methyl fumarates were first investigated 
for their anti­proliferative and anti­oxidant effects; 
however, they quickly became repurposed for use 
as potent anti­psoriatic drugs in Europe[7]. We have 
investigated the usefulness of DMF and reported its 
effects on acute[8] and chronic pancreatitis[9]. However, 
to our knowledge, the effects of DMF on liver I/RI have 
not been investigated. The aim of the present study 
was to test the hypothesis that treatment with the 
potent anti­oxidant DMF may attenuate the severity 
of liver I/RI in experimental animals by upregulating 




Sprague­Dawley male rats weighing 230­250 g were 
purchased from Charles River (Wilmington, MA, 
United States). The rats were free of all pathogens 
and housed under standard conditions (room tempera­
ture: 22 ℃: humidity: 50% ± 5%, 12:12 h light/dark 
cycle). The study was approved by the Institutional 
Animal Care and Use Committee of the University of 
California, Irvine.
Experimental design
The rats were randomly divided into 3 experimental 
groups: (1) the sham group (n = 6) was subjected to 
exposure of the hepatic artery, portal vein, and bile 
duct region but no I/RI; (2) the control (CTL) group (n 
= 7) was subjected to 1 hour of ischemia followed by 
2 h of reperfusion. Finally; and (3) the DMF group (n = 
6) received DMF (25 mg/kg, twice/d) by oral gavage 2 
d prior to the operation. 
DMF administration
Stock solutions of DMF (Sigma, St. Louis, MO, 
United States) were prepared in dimethyl sulfoxide 
(DMSO) (Hybri­MAX, St. Louis, MO, United States). 
Experimental rats were given oral DMF (25 mg/kg, 
twice/day) dissolved in methyl cellulose (Sigma, 
St. Louis, MO, United States). Intragastric gavage 
administration was conducted in conscious animals 
using straight gavage needles appropriate for the 
animal size.
Surgical procedure
Under general anesthesia using isoflurane, a midline 
incision was made. The left and median portal triads 
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were occluded by a microvascular clamp to achieve 
70% liver ischemia. After 1 h of clamping, the clamp 
was removed, and restored hepatic blood flow was 
confirmed visually prior to wound closure. During 
the surgery, the body temperature was maintained 
at approximately 37.5 ℃ with a heating blanket. Two 
hours post clamp removal (reperfusion time), blood 
samples and ischemic liver lobes were collected under 
deep general anesthesia for analysis, and the animals 
were sacrificed[10].
Histopathological analysis
Histopathological analysis was performed as previously 
described[11]. The severity of I/RI was blindly graded 
using the modified Suzuki criteria[12].
Assessment of hepatic apoptosis
Apoptosis was quantified by the terminal de­
oxynucleotidyl transferase (TdT)­mediated dUTP nick­
end labeling (TUNEL) technique (Millipore, Bedford, 
MA, United States). For each section, 20 random 
fields were examined by confocal microscopy (20 × 
objective). An apoptotic index (i.e., the number of 
nuclei labeled by the TUNEL method/the total number 
of nuclei) was calculated[13].
Measurement of serum alanine aminotransferase and 
malondialdehyde 
Serum alanine aminotransferase (ALT) levels were 
determined to assess the liver function using commer­
cial kits (BioVision, Milpitas, CA, United States) 
according to the manufacturer’s instructions. The 
serum malondialdehyde (MDA) formation assay 
was performed using a thiobarbituric acid reactive 
substances (TBARS) assay kit (Cayman, Ann Arbor, 
MI, United States) according to the manufacturer’s 
instructions.
Adenosine triphosphate determination
The adenosine triphosphate (ATP) levels of liver tissue 
were determined using a colorimetric/fluorometric 
assay kit (Bio Vision, Milpitas, CA, United States) 
according to the manufacturer’s instructions. We used 
20 mg of liver tissue for the assay and calculated the 
ATP content. Protein concentration was performed with 
a BioRad assay kit (Bio­Rad, Richmond, CA, United 
States) based on the Lowry method[14].
Myeloperoxidase assay
The presence of myeloperoxidase (MPO) was used as 
an index of neutrophil accumulation in the liver[15] and 
was determined using an MPO colorimetric assay kit 
(BioVision, Milpitas, CA, United States) according to 
the manufacturer’s instructions.
Protein extraction and Western blots
Western blots were performed as previously des­
cribed[11]. The following reagents were used: rabbit 
polyclonal antibody to cyclooxygenase­2 (COX­2) 
(AbcamInc, Cambridge, MA, United States), glutamate­
cysteine ligase modifier subunit (GCLM) (AbcamInc, 
Cambridge, MA, United States), inducible nitric oxide 
(NO) synthase (iNOS) (Santa Cruz Biotechnology, 
Santa Cruz, CA, United States), endothelial NO 
synthase (eNOS) (Santa Cruz Biotechnology, Santa 
Cruz, CA, United States), glutamate­cysteine ligase 
catalytic subunit (GCLC) (AbcamInc, Cambridge, 
MA), glutathione (GSH) peroxidase (GPx) (AbcamInc, 
Cambridge, MA, United States), heme oxygenase­1 
(HO­1) (AbcamInc, Cambridge, MA, United States), 
superoxide dismutase (SOD) (Santa Cruz Biotechnology, 
Santa Cruz, CA, United States), glyceraldehyde­3­
phosphate dehydrogenase (GADPH) (Cell Signaling, 
Danvers, MA, United States), rabbit monoclonal antibody 
to NF­κB (Cell Signaling, Danvers, MA, United States), 
catalase (CAT) (Rockland Immunochemicals, Limerick, 
PA, United States), and mouse monoclonal antibody to 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) 
quinone oxidoreductase­1 (NQO­1) (AbcamInc, 
Cambridge, MA, United States) followed by secondary 
anti­rabbit or mouse immunoglobulin G (Cell Signaling, 
Danvers, MA, United States).
Measurement of serum inflammatory mediators
The levels of serum inflammatory mediators were 
determined using a standard rat cytokine kit (Ray 
Biotech, Norcross, GA, United States) according to 
the manufacturer’s instructions. Fifteen rat cytokines/
chemokines were analyzed.
Statistical analyses
All the results are presented as the mean ± SD. 
Comparisons between two groups were performed 
with Student’s t­test or Mann­Whitney’s U test, as 
appropriate, using Stat View­J 5.0 software (SAS, 
Cary, NC, United States). Statistical significance was 
defined as a P value less than 0.05.
RESULTS
Histopathological changes
The histopathological findings are given in Figure 1A 
and B. The liver tissue was histologically normal in 
the sham group (Figure 1A). In contrast, substantial 
intracellular vacuolization, sinusoidal dilatation, 
congestion, and focal necrosis of the liver parenchyma 
were observed in the CTL group (Figure 1A). These 
changes were notably reduced in the DMF treatment 
group (Figure 1A). The Suzuki scores of the groups 
differed significantly (CTL 9.3 ± 0.5 vs DMF 2.5 ± 1.2, 
P < 0.0001; Figure 1B), indicating that pretreatment 
with DMF ameliorated the I/RI­induced histological 
changes.
Effect of DMF on hepatocellular apoptosis
Representative confocal microscopy images of 
hepatocyte­labeling TUNEL (green fluorescence) are 
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cellular ATP levels. DMF­treated livers demonstrated 
significantly higher ATP contents than those in the CTL 
group (20.3 ± 0.4 nmol/mg vs 18.3 ± 0.6 nmol/mg, 
respectively, P = 0.02; Figure 2C).
Neutrophil infiltration in the DMF-treated group, as 
analyzed by MPO activity, was significantly lower (7.8 
± 0.4 mU/mL) than that in the CTL group (6.0 ± 0.5 
mU/mL) (Figure 2D, P = 0.01), indicating that DMF 
treatment decreased neutrophil migration into the 
hepatocytes.
Effect of DMF on the activities of anti-oxidant enzymes 
in liver tissue
Figure 3B­D shows the protein expression of 
nuclear factor erythroid 2­related factor 1 (Nrf2) 
pathway target anti­oxidant enzymes. CAT and 
GCLM expression levels in the liver were significantly 
enhanced by DMF treatment compared with those 
in the CTL group (CAT: 1.50 ± 0.18­fold vs 0.93 ± 
0.13­fold, respectively, P = 0.03, Figure 3B; GCLM: 
0.42 ± 0.07­fold vs 0.22 ± 0.05­fold, respectively, P = 
0.04, Figure 3C). Additionally, GCLC protein expression 
was higher in the DMF group than in the CTL group 
(CTL: 0.48 ± 0.08­fold vs DMF 0.77 ± 0.13­fold, P 
= 0.10; Figure 3D). The protein expression levels of 
GPx, HO-1, SOD and NQO-1 did not differ significantly 
between the two groups (GPx: P = 0.22, HO­1: P = 
shown in Figure 1C and D. No TUNEL­positive apoptotic 
cells were found in the sham group. Although the 
number of TUNEL­positive apoptotic cells increased 
dramatically in the CTL group, only a few positive cells 
were detected in the DMF group. The apoptotic index 
in the DMF group (1.3 ± 0.9) was significantly lower 
than that of the CTL group (17.2 ± 3.6) (Figure 1D; P 
= 0.002). These results suggest that DMF protected 
the liver from hepatocellular apoptosis.
Effect of DMF on serum ALT and MDA
To further confirm the protective effect of DMF on 
hepatic I/R injury, the level of ALT, a hepatocyte 
damage marker, was measured. The ALT levels were 
significantly lower in the DMF group than in the CTL 
group (5026 ± 2305 U/L vs 10592 ± 1152 U/L, 
respectively, P = 0.04; Figure 2A). To determine the 
cellular damage under oxidative stress after I/RI, the 
serum MDA level, which is a valid biochemical marker 
of lipid peroxidation, was measured. The serum MDA 
levels were significantly lower in the DMF group (DMF 
18.2 ± 1.4 µmol/L vs CTL 26.0 ± 1.0 µmol/L, P = 
0.0009; Figure 2B). 
Effect of DMF on ATP content and MPO activity in 
hepatocytes
To assess the ability of hepatocytes, we studied the 
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Figure 1  Liver ischemia/reperfusion injury in a rat model. A: Hematoxylin and eosin (H&E)-stained histology of rat liver subjected to 60 min of ischemia and 2 h of 
reperfusion. The levels of substantial intracellular vacuolization, sinusoidal dilatation, congestion, and focal necrosis of the liver parenchyma in the dimethyl fumarate 
(DMF) group were significantly improved compared to those of the CTL group; B: Liver histology damage scoring (Suzuki score). Data represent the mean ± SD. 
Pretreatment with DMF ameliorated ischemia/reperfusion injury (I/RI)-induced histological changes; C: TUNEL staining of rat liver subjected to 60 min of ischemia and 
2 h of reperfusion. The DMF-treated group had significantly fewer TUNEL-positive cells (green fluorescence) than the CTL group; D: Apoptotic index indicating that 
pretreatment with DMF improved I/RI-induced apoptosis (P ≤ 0.01). Data represent the mean ± SD. DMF: Dimethyl fumarate; CTL: Control.
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0.39, SOD: P = 0.32 and NQO­1: P = 0.95).
Effect of DMF on iNOS and eNOS expression
To determine whether DMF exerts its protective 
role through NO­mediated production, we detected 
the levels of NO synthases (eNOS and iNOS). The 
protein expression of eNOS was enhanced by DMF 
administration relative to that in the CTL group (0.38 
± 0.05­fold vs 0.17 ± 0.06­fold, respectively, P = 0.02; 
Figure 3F). However, no significant difference in iNOS 
expression was found between the two groups (CTL: 
0.027 ± 0.12­fold vs DMF 0.027 ± 0.009­fold, P = 
0.97).
Effect of DMF on NF-κB and COX-2 expression
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Figure 2  Effect of dimethyl fumarate on serum alanine aminotransferase and malondialdehyde and liver adenosine triphosphate and myeloperoxidase. 
The levels of serum alanine aminotransferase (ALT) (A) and malondialdehyde (MDA) (B) and liver adenosine triphosphate (ATP) (C) and myeloperoxidase (MPO) 
(C) in the liver tissue were determined. Serum ALT and MDA in the DMF group were significantly lower than in the CTL group (ALT: P < 0.05, MDA: P < 0.001; data 
represent the mean ± SD). Liver ATP in the DMF group was significantly higher than in the CTL group (P < 0.05; data represent the mean ± SD). Liver MPO in the 
DMF group was significantly lower than in the CTL group (P < 0.05; data represent the mean ± SD). DMF: Dimethyl fumarate; CTL: Control.
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Figure 3  Effects of dimethyl fumarate on the expression levels of anti-oxidant enzymes, endothelial nitric oxide synthase, NF-κB and cyclooxygenase-2 
in the liver. A: Representative western blots of CAT, GCLM, GCLC, GPx, eNOS, NF-κB and COX-2 in the CTL and dimethyl fumarate (DMF) groups. The bar graph 
summarizing the western blot data of (B) CAT, (C) GCLM, (D) GCLC, (E) GPx, (F) eNOS, (G) NF-κB, and (H) COX-2. Data represent the mean ± SD. Significant 
increases in liver CAT and GCLM expression levels were observed in the DMF group compared to those in the CTL group (CAT: P = 0.03, Figure 3B; GCLM: P = 
0.04, Figure 3C). The protein expression of eNOS was also enhanced by DMF administration compared to that of the CTL group (P = 0.02, Figure 3F). Furthermore, 
DMF decreased the levels of NF-κB and COX-2 expression in the liver (NF-κB, P = 0.01, Figure 3G; COX-2, P = 0.007, Figure 3H). The protein expression levels of 
GPx, HO-1, SOD and NQO-1 were not significantly different between the two groups (GPx: P = 0.22, HO-1: P = 0.39, SOD: P = 0.32 and NQO-1: P = 0.95). GCLM: 
Glutamate-cysteine ligase modifier subunit; COX-2: Cyclooxygenase-2; GCLC: Glutamate-cysteine ligase catalytic subunit; eNOS: Endothelial nitric oxide synthase; 
GPx: Glutathione peroxidase; DMF: Dimethyl fumarate; CTL: Control.
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western blot analysis of NF­κB and COX­2 proteins 
were performed. Both the expression levels of both NF­
κB and COX­2 decreased significantly in DMF­treated 
animals’ liver tissues (NF­κB: CTL: 0.75 ± 0.08­fold vs 
DMF 0.44 ± 0.04­fold, P = 0.01, Figure 3G; COX­2: 
CTL: 1.64 ± 0.26­fold vs DMF 0.48 ± 0.19­fold, P = 
0.007; Figure 3H) compared to those of the CTL group. 
Effect of DMF on the production of cytokines and 
chemokines
We analyzed direct changes in serum cytokine and 
chemokine production in response to I/RI. DMF 
administration significantly decreased the serum levels 
of many inflammatory mediators relative to those 
in the CTL group (Figure 4). Significant reductions 
of the following were observed in the DMF­treated 
group: cluster of differentiation 86 (CD86), cytokine­
induced neutrophil chemoattractant­2α (CINC­2α), 
CINC­3, ciliary neurotrophic factor (CNTF), Fas ligand, 
interleukin-6 (IL-6), IL-10, macrophage inflammatory 
protein­3α (MIP­3α), platelet­derived growth factor­
AA (PDGF­AA), tissue inhibitor of metalloproteinase 1 
(TIMP­1), tumor necrosis factor α (TNF­α) and vascular 
endothelial growth factor (VEGF).
DISCUSSION
In this study, we evaluated the effects of DMF, a 
potent anti­oxidant, on a rodent hepatic I/RI model. 
Our data demonstrated that the pharmacological 
supplementation of DMF resulted in a significant 
increase of anti­oxidant enzymes and a substantial 
reduction of inflammatory mediators, leading to 
significant amelioration of the liver damage caused by 
I/R. Many studies have shown that oxidative stress 
plays a crucial role in the pathogenesis of I/RI[16]. MDA 
is an indicator of lipid peroxidation and cellular damage 
under oxidative stress, and the elevation of MDA is 
associated with liver I/RI[17]. We observed that the 
MDA levels were significantly decreased in the DMF­
treated rats, suggesting lower I/RI­induced oxidative 
stress in the DMF­treated liver. ROS can be contained 
by endogenous anti­oxidant enzymes, such as SOD, 
CAT and GPx[1]. ROS­induced lipid peroxidation can 
be blocked by these anti­oxidative enzymes. CAT is 
an anti­oxidant enzyme that converts H2O2 to water 
and thereby prevents the transformation of H2O2 
into highly toxic hydroxyl radicals. Previous reports 
showed that CAT has beneficial effects toward the 
end of the ischemic period and that its activities 
are decreased after I/RI[18]. GSH protects cells from 
oxidative injury by scavenging radicals and reducing 
lipid peroxidation products. GSH is synthesized by 
GSH synthetase and glutamate­cysteine ligase (GCL), 
which is a heterodimer composed of GCLM and GCLC 
subunits. Both GCLM and GCLC are upregulated for 
GSH synthesis by oxidants, providing a protective 
mechanism against oxidative stress[19]. We observed 
that DMF increased CAT, GCLM and GCLC expression, 
which may explain the observed decrease in ROS­
related liver damage.
The accumulation of neutrophils, as confirmed 
by measuring the MPO activity, was significantly 
reduced by the administration of DMF. Neutrophils 
are believed to mediate hepatic damage caused by 
the production of ROS and reactive halogen species. 
These toxic products can directly damage hepatocytes 
and endothelial cells and induce other inflammatory 
mediators[20]. The initial phase of injury, which occurs 

































































Figure 4  Inflammatory mediator production in rat serum. Dimethyl fumarate (DMF) significantly reduced the production of inflammatory mediators in the serum 
relative to the CTL group. Significant reductions of CD86, CINC-2α, CINC-3, CNTF, Fas ligand, IL-6, IL-10, MIP-3α, PDGF-AA, TIMP-1, TNF-α and VEGF were 
observed in the DMF-treated group. Data represent the mean ± SD (aP < 0.05, bP < 0.01, eP < 0.001). DMF: Dimethyl fumarate; CTL: Control; IL: Interleukin; CD86: 
Cluster of differentiation 86; CINC-2α: Cytokine-induced neutrophil chemoattractant-2α; CNTF: Ciliary neurotrophic factor; MIP-3α: Macrophage inflammatory protein-
3α; PDGF-AA: Platelet-derived growth factor-AA; TIMP-1: Tissue inhibitor of metalloproteinase 1; TNF-α: Tumor necrosis factor α; VEGF: Vascular endothelial growth 
factor.
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cell­induced oxidant stress. Activated Kupffer cells 
produce and secrete pro­inflammatory cytokines, 
including TNF­α, IL­6, COX­2, and iNOS[3]. In this 
study, we observed significantly decreased TNF-α, IL­6 
and COX­2 protein expression, indicating that DMF 
may inhibit the activation of Kupffer cells by enhancing 
anti­oxidant effects. We also found a significant 
decrease in the expression level of NF­κB 2 h after 
reperfusion in the DMF­pretreated rats. A previous 
report showed that DMF inhibited pro­inflammatory 
cytokine production and NF­κB signaling by inhibiting 
nuclear translocation[21]. Previous reports also 
demonstrated that DMF has a cardioprotective effect 
during I/RI through the Nrf­2 and NF­κB pathway[22], 
strongly supporting our results. Moreover, recent 
studies have demonstrated that NF­κB is involved in 
the regulation of COX­2 and iNOS expression[3]. Our 
data showed that DMF can inhibit NF­κB expression 
and suppress COX­2 expression but does not affect 
iNOS expression.
We found that twelve plasma cytokines and 
chemokines were decreased by DMF administration. 
CINC and MIP are members of the CXC chemokine 
family, are potent chemotactic factors for neutrophils, 
and contribute to neutrophil recruitment in in­
flammation[23]. MIP­3α is expressed mainly in the liver 
and is produced by dendritic cells and macrophages 
after an inflammatory response, resulting in the 
recruitment of activated T cells into the liver[24]. CD86 
was also reported to be involved as the costimulatory 
signaling molecule for antigen­presenting cells (APCs) 
in T­cell activation[25]. The up­regulation of CD86 
in sinusoidal endothelial cells contributes to liver 
injury after warm I/R[26]. VEGF is a well­established 
angiogenesis factor and has been recently found to 
have potent pro-inflammatory properties in the early 
period after transplant[27]. PDGF­AA is an important 
mediator of connective tissue expansion during liver 
fibrosis[28]. TIMP-1 is significantly increased in patients 
with fulminant hepatitis, reflecting severe hepatic 
inflammation[29]. Fas ligand is expressed on infiltrating 
immune cells and induces apoptosis of hepatocytes, 
leading to hepatocyte injury[30]. CNTF, a member of 
the IL­6 superfamily, is involved in fever induction 
and a hepatic acute­phase protein response[31]. Taken 
together, DMF suppressed plasma cytokines and 
chemokines related to apoptosis, inflammation and 
fibrosis. Further studies will be conducted to explore 
this Nrf2 anti-inflammatory effect.
The histological investigation suggested that I/RI 
caused severe pathological alterations in the liver. 
Pretreatment with DMF ameliorated I/RI­induced 
histological changes, and this effect was attributed 
to its anti­oxidant efficacy. The observed endothelial 
dysfunction could be a consequence of decreased 
synthesis or bioavailability of NO[32]. A previous report 
showed that the observed endothelial dysfunction is 
characterized by a marked reduction in NO availability 
and decreased expression and phosphorylation of 
eNOS[17]. Our results showed that DMF enhanced 
eNOS protein expression, suggesting that DMF 
pretreatment may protect endothelial function from 
I/RI. Furthermore, cellular apoptosis consumes large 
amounts of nicotinamide adenine dinucleotide (NAD+), 
and the process to resynthesize NAD+ decreases the 
level of cellular ATP[33]. Our data showed that the ATP 
content was increased in the DMF group compared 
to that in the CTL group, suggesting that DMF has an 
anti­apoptotic effect. In fact, the apoptotic index in the 
DMF group was significantly lower than that in the CTL 
group. A previous report showed that liver I/RI mainly 
occurred in the form of apoptosis[13]. Excessive oxygen 
free radicals could directly react with unsaturated fatty 
acids on the surfaces of mitochondrial membranes, 
leading to the destruction of their structure and 
function. Large amounts of cytochrome C and other 
apoptosis­promoting substances were released, 
triggering cell apoptosis. In this study, we showed 
that DMF may have inhibited the apoptotic pathway 
mediated by mitochondria.
In conclusion, our biochemical and histological 
findings indicated that DMF pretreatment was very 
effective in preventing tissue damage in liver I/RI. 
First, the burden of oxidative stress, which increases 
during I/RI, was alleviated by DMF, which increased 
the expression of anti­oxidant enzymes and decreased 
the level of NF­κB. Second, DMF improved the 
recovery of endothelial dysfunction and the production 
of ATP in hepatocytes. Other protective effects against 
I/RI on hepatocytes were clearly demonstrated by 
DMF administration, including improvements in the 
ALT level and the histopathological features. Future 
studies are needed to explore the efficacy of DMF in 
the management of patients with liver interventions.
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